The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

PURPOSE: The development of blood biomarkers that reflect Alzheimer’s disease (AD) pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests for dementia differential diagnosis and early detection. In 2019, the Geneva AD Biomarker Roadmap Initiative included blood bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V., Hansson, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175325/
https://www.ncbi.nlm.nih.gov/pubmed/33677733
http://dx.doi.org/10.1007/s00259-021-05253-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175325/
https://www.ncbi.nlm.nih.gov/pubmed/33677733
http://dx.doi.org/10.1007/s00259-021-05253-y

Ejemplares similares